Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Symptom Management

A paradigm shift in the management of relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin lymphoma (NHL) has developed in recent years. With increased use of targeted therapies, ibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, is an integral therapeutic option for patients with treatment-naïve and treatment-experienced CLL or low-grade NHL. Ibrutinib therapy demonstrated superior overall response rates compared with ofatumumab and other agents in treatment-experienced patients with CLL.
Patients can be successfully managed with minimal opioid medication after urologic oncology surgery, said Kerri Stevenson, MN, NP-C, RNFA, CWOCN, Lead Advanced Practice Provider – Interventional Radiology, Stanford Health Care, CA, at the 2018 ASCO Quality Care Sym­posium.
Anthracyclines, such as doxorubicin or epirubicin, have been used for decades for the treatment of a variety of cancers, including breast cancer, sarcoma, lymphoma, and leukemia.

This symptom management article describes the approach to rasburicase-induced hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency, which may occur intravascularly in this patient population.

For patients diagnosed with cancer, the annual incidence of VTE is approximately 20%, and the risk for VTE in this patient population is estimated to be 7 times higher than in the general population.

Targeting and inhibiting the vascular endothelial growth factor (VEGF)-signaling pathway has become an integral modality in the treatment of a variety of malignancies, including renal-cell carcinoma (RCC); glioblastoma; hepatocellular carcinoma; gastrointestinal stromal tumors; and colorectal, lung, gastric, and ovarian cancers.
This section provides a quick update of symptomatic conditions in oncology and their management. Readers are invited to submit brief updates following the guidelines at www.JHOPonline.com.

Results 1 - 7 of 7